- Conditions
- Colorectal Cancer
- Interventions
- All eligible subjects will provide blood for SEPT9 biomarker testing
- Other
- Lead sponsor
- Epigenomics, Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 7,929 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 20
- States / cities
- Boca Raton, Florida • Miami, Florida • Atlanta, Georgia + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Human Papillomavirus Infection, Stage I Oral Cavity Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oral Cavity Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oral Cavity Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Durvalumab, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
- Biological · Other · Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Pain, Postoperative
- Interventions
- Surgical patients' clinical progression, Genetic markers
- Behavioral · Genetic
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 428 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- bortezomib, carboplatin, etoposide, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression, Bipolar Depression
- Interventions
- Ketamine
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Lymphoma, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • Houston, Texas
- Conditions
- Advanced Solid Tumor
- Interventions
- Hyperpolarized 13C-Pyruvate, Magnetic Resonance Imaging (MRI), 13C,15N-Urea
- Drug · Procedure
- Lead sponsor
- Robert Bok, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Stroke, Gait Disorders, Neurologic
- Interventions
- REEV SENSE, Motion capture system
- Device
- Lead sponsor
- REEV LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Cigarette Smoker, Current Smoker, Former Smoker, Multiple Pulmonary Nodules, Pulmonary Nodule
- Interventions
- Computed Tomography, Fludeoxyglucose F-18, Fluorine F 18 L-glutamate Derivative BAY94-9392, Positron Emission Tomography (PET/CT)
- Diagnostic Test · Drug
- Lead sponsor
- Andrei Iagaru
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- bortezomib, paclitaxel, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Ependymoma
- Interventions
- HLA-A2 restricted synthetic tumor antigen, Imiquimod, enzyme-linked immunosorbent assay, flow cytometry, immunohistochemistry staining method, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- James Felker
- Other
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Breast Carcinoma, Colorectal Carcinoma, Community Practice, Lung Carcinoma, Melanoma, Solid Neoplasm
- Interventions
- Survey Administration
- Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- Not listed
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Adult Solid Neoplasm, Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Interventions
- Computed Tomography, Fluorothymidine F-18, Laboratory Biomarker Analysis, Pharmacological Study, Positron Emission Tomography, Sunitinib Malate
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Inclusion Body Myositis
- Interventions
- PAMSys pendant PAMSys wrist sensors
- Device
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 20 participants
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Post-infectious Irritable Bowel Syndrome, Irritable Bowel Syndrome
- Interventions
- Not listed
- Lead sponsor
- University of Nevada, Reno
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Reno, Nevada
- Conditions
- Overweight and Obesity
- Interventions
- Pecan snack, Tortilla chip snack
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 20 Years to 50 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Healthy Subject, Tobacco Use Disorder
- Interventions
- Laboratory Biomarker Analysis, Phytochemical, Placebo, Screening Questionnaire Administration
- Other · Dietary Supplement
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Colorectal Cancer Stage II, Colorectal Cancer Stage III
- Interventions
- RO7198457 intravenous (IV), Observational group (no intervention)
- Drug · Other
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 15
- States / cities
- Greenbrae, California • Indianapolis, Indiana • Minneapolis, Minnesota + 12 more
- Conditions
- Multiple Sclerosis
- Interventions
- Blood sample collection for coagulation profile
- Diagnostic Test
- Lead sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- Foundation for the National Institutes of Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Minneapolis, Minnesota • Salt Lake City, Utah
- Conditions
- Hepatobiliary Diseases
- Interventions
- Not listed
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 430 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2022
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Renal Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Atezolizumab, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Nelfinavir Mesylate, Nivolumab, Pembrolizumab
- Drug · Radiation · Other + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Myofascial Pain Syndrome, Healthy
- Interventions
- Ultrasound imaging, Bioimpedance spectroscopy, Electromyography, Physical examination
- Diagnostic Test
- Lead sponsor
- George Mason University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Fairfax, Virginia
- Conditions
- Treatment Resistant Depression (TRD)
- Interventions
- Ketamine (0.25 mg/kg), Ketamine (0.5 mg/kg), Ketamine (0.75 mg/kg)
- Drug
- Lead sponsor
- Soterix Medical
- Industry
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York